← All news
Markets
Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine
2 outlets - including Financialpost and Fortune - are covering this story. Wall Street sees new treatments as an untapped goldmine, full of consumers who are willing to pay out-of-pocket for better options
Covered by 2 outlets
All coverage · 2 articles
Financial Post
·Aug 31, 13:51 UTC
Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine
Wall Street sees new treatments as an untapped goldmine, full of consumers who are willing to pay out-of-pocket for better options
Fortune
·Aug 29, 15:11 UTC
Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine
Pattern hair loss affects an estimated 50 million men and 30 million women in the US, but there have been no new approved drugs since the late 1990s.